Random-effects models also revealed that AID use was associated with reduced time spent in hypoglycemia (<3.9 mml/L; MD = −0.32%; 95% CI, −0.60% to −0.03%; I2 = 18%) and hyperglycemia (>10 mmol/L; MD = −10.8%; 95% CI, −14.4% to −7.2%; I2 = 55%), particularly during the night (MD = −14.4%; 95% CI, −19.9% to −8.9%; I2 = 79%) compared with any insulin regimen. The gene discussed is INS; the disease is Hyperglycemia.